Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.67 |
| ▸ | F3 | P13726 | 2/20 | 0.67 |
| ▸ | IKBKB | O14920 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | XBP1 | P17861 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.59 |
| ▸ | MGAM | O43451 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | SI | P14410 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18229770 | 1.00 | HSD11B1 (1.00) | HSD11B1EGFRCYP1A2F3IKBKB | |
| SCHEMBL18229769 | 1.00 | HSD11B1 (1.00) | HSD11B1EGFRCYP1A2F3IKBKB | |
| SCHEMBL1524445 | 0.86 | HSD11B1 (0.76) | HSD11B1EGFRCYP1A2F3IKBKB | |
| SCHEMBL643539 | 0.86 | HSD11B1 (0.76) | HSD11B1EGFRCYP1A2F3IKBKB | |
| SCHEMBL643540 | 0.86 | HSD11B1 (0.76) | HSD11B1EGFRCYP1A2F3IKBKB | |
| SCHEMBL17077430 | 0.83 | EGFR (1.00) | HSD11B1EGFRCYP1A2NFE2L2 | |
| SCHEMBL17077433 | 0.83 | EGFR (1.00) | HSD11B1EGFRCYP1A2NFE2L2 | |
| SCHEMBL2717308 | 0.82 | HSD11B1 (0.70) | HSD11B1EGFRCYP1A2F3IKBKB | |
| SCHEMBL182195 | 0.82 | HSD11B1 (0.70) | HSD11B1EGFRCYP1A2F3IKBKB | |
| SCHEMBL182196 | 0.82 | HSD11B1 (0.70) | HSD11B1EGFRCYP1A2F3IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250255853-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2025-08-14 | — | — | US | disclosed |
| US-20240285592-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2024-08-29 | — | — | US | disclosed |
| US-20220152001-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2022-05-19 | — | — | US | disclosed |
| US-11266634-B2 | Methods for treating melanoma with human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2022-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11266634-B2 | Methods for treating melanoma with human therapeutic agents | HNMT, INMT, TYR | HSD11B1 2815/4885EGFR 3977/4885CYP1A2 3241/4885 |
| US-20240285592-A1 | HUMAN THERAPEUTIC AGENTS | INMT, NLN, MYC | HSD11B1 3453/4885EGFR 3349/4885CYP1A2 2789/4885 |
| US-20220152001-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | HSD11B1 2836/4885EGFR 3201/4885CYP1A2 2166/4885 |
| US-20250255853-A1 | HUMAN THERAPEUTIC AGENTS | HASPIN, TIPARP, SHARPIN | HSD11B1 4358/4885EGFR 3389/4885CYP1A2 4193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.